摘要
目的 :评价安君宁治疗海洛因依赖者稽延性戒断症状 (PWS)的效果及不良反应。方法 :将符合ICD— 10海洛因依赖者随机分成 3组 ,即安君宁治疗组、多虑平治疗组、安慰剂组。采用双盲双模拟给药方法 ,进行为期 30d的抗PWS的治疗比较。选用的量表有“稽延性戒断症状评定量表”、“HAMA焦虑量表”、“药物渴求量表”。结果 :PWS量表显示安君宁与多虑平比较差异无显著性 (P >0 0 5 ) ,与安慰剂组在d10、d15、d2 0、d2 5、d30有非常显著性差异 (P<0 0 1)。HAMA量表评分安君宁与多虑平比较差异无显著性 (P >0 0 5 ) ,与安慰剂比较差异有显著性 (P <0 0 1)。安君宁控制药物渴求方面与安慰剂组比较有非常显著性差异 (P <0 0 1)。安君宁不良反应较少。结论 :安君宁治疗稽延性戒断症状 ,疗效可靠、安全 。
Objective: To assess the effect and adverse reaction of Anjunning in the treatment of protracted withdrawal symptoms (PWS) of heroin dependence. Methods: The heroin addicts who met ICD-10 criteria were randomized to three groups, Anjunning group, Doxepine group and Placebo group. All dosing was double blind and double dummy. The duration of treatment was 30 days. The evaluation instruments included the Scale of PWS, HAMA, the Scale of Drug Craving. Results: PWS score of Anjunning group was comparable with the score of Doxepine group during the whole treatment period; and lower than that of Placebo group during d10-30 of the treatment (P<0.01). HAMA and craving scores of Anjunning group were also similar to those of Doxepine group (P>0.05) and lower than those of Placbo group (P<0.01). There were only a few adverse reactions and little craving for heroin in Anjunning group. Conclusion: Anjunning is safe and effective in controlling PWS. The efficacy of Anjunning was comparable with Dexopine.
出处
《中国药物依赖性杂志》
CAS
CSCD
2003年第4期276-279,共4页
Chinese Journal of Drug Dependence
基金
北京市科委专项资金资助
课题合同号H0 10 6 10 6 0 0 113
